文献速递肝病

支链氨基酸补充未能改善肝硬化患者肌少症指标:一项随机对照试验

Branched-chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial.
PubMed 文献 · Aliment Pharmacol Ther · 2024-02-26

该12个月双盲随机对照试验纳入150例肝硬化且肌力下降的志愿者,比较每日30g支链氨基酸(BCAA)与等热量等氮乳清蛋白。12个月时两组达到主要终点比例分别为57%和61%(p=0.80),握力和上肢瘦体重无显著组间差异,其他体成分、体能、衰弱、住院或死亡也无差异。

要点

  • BCAA每日30g未改善肝硬化患者握力或上肢瘦体重。
  • BCAA组与乳清蛋白组在体能、衰弱、住院和死亡方面无显著差异。
  • BCAA组异味副作用报告率更高(p=0.045)。

核心结论

  • 在随机对照条件下,BCAA补充相比乳清蛋白补充未改善肝硬化患者肌力、肌肉量、体能或躯体衰弱。

研究设计与样本

  • 12个月双盲随机对照试验,纳入150例肝硬化且肌力下降的志愿者(BCAA组74例,对照组76例)。
  • 干预为每日30g BCAA,对照为等热量等氮乳清蛋白。
  • 主要终点为握力和DEXA测量的上肢瘦体重增加。

主要发现

  • 12个月时BCAA组57%、对照组61%达到主要终点(p=0.80)。
  • 12个月握力组间平均校正差异为-0.15 kg(95%CI -0.37至0.06,p=0.29)。
  • 12个月上肢瘦体重组间平均校正差异为1.7 kg(95%CI -0.2至3.6,p=0.22)。
  • 其他体成分参数、体能、衰弱、住院率或死亡率无显著组间差异。
  • 全体队列疲劳改善,无显著组间差异;15%志愿者报告副作用,BCAA组异味更高(p=0.045)。

临床怎么用

  • 对于肝硬化合并肌少症患者,不应仅依赖BCAA补充来改善肌力或肌肉量。
  • BCAA与乳清蛋白在肌少症相关指标上效果相当,选择时需考虑异味等耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia is associated with adverse outcomes in cirrhosis. Branched-chain amino acids (BCAA) target several pathways that lead to muscle loss in this population. AIMS: We aimed to evaluate the impact of BCAA supplementation on sarcopenia measures in patients with cirrhosis. METHODS: We conducted a 12-month double-blinded, randomised, controlled trial of BCAA supplementation (30 g daily) compared to an equicaloric, equi-nitrogenous whey protein in volunteers with cirrhosis and reduced muscle strength. The primary endpoint was an increase in grip strength and upper limb lean mass measured on DEXA. Mean-adjusted differences (MAD, 95% CI) between groups at 6 and 12 months are reported as treatment effect using a linear mixed model for repeated measures. RESULTS: A total of 150 volunteers entered the trial (74 BCAA, 76 control), with a median age of 58 years [IQR 48; 63] and MELD of 14 [12; 17]. At 12 months, 57% in the BCAA arm and 61% in the control arm met the primary endpoint (p = 0.80). No significant between-group difference was found in grip strength (MAD -0.15 kg [-0.37; 0.06], p = 0.29) or upper limb lean mass (1.7 kg [-0.2; 3.6], p = 0.22) at 12 months. No significant differences in other body composition parameters, physical performance, frailty, rates of hospitalisation or mortality were found between the BCAA and the control group. Fatigue improved across the entire cohort, without significant between-group differences. 15% of volunteers reported side effects, with distaste higher in the BCAA arm (p = 0.045). CONCLUSION: BCAA supplementation did not improve measures of muscle strength, mass or performance or physical frailty compared to a whey protein supplement in a randomised controlled setting. ACTRN12618000802202.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hey P, Hoermann R, Sinclair M, et al. Branched-chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial. Aliment Pharmacol Ther. 2024. PMID: 38404263. doi:10.1111/apt.17917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。